The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Adc Therapeutics SA shares valued at $1,124,000 were purchased by Redmile Group, LLC on Jul 01 ’24. At $2.81 per share, Redmile Group, LLC acquired 400,000 shares. The insider’s holdings grew to 15,669,217 shares worth approximately $46.69 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Redmile Group, LLC purchased 400,000 shares, netting a total of over 1,124,000 in proceeds. Following the buying of shares at $2.81 each, the insider now holds 12,995,040 shares.
Before that, Azelby Robert had sold 6,995 shares from its account. In a trade valued at $20,216, the Director traded Adc Therapeutics SA shares for $2.89 each. Upon closing the transaction, the insider’s holdings decreased to 6,995 shares, worth approximately $0.16 million.
As published in their initiating research note from Cantor Fitzgerald on May 30, 2024, Adc Therapeutics SA [ADCT] has been an Overweight. Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in late March. As of August 10, 2023, JP Morgan has increased its “an Underweight” rating to a “Neutral” for ADCT. Earlier on April 24, 2023, BofA Securities downgraded its rating. Their new recommendation was “an Underperform” for ADCT stock which previously was a “a Neutral”.
Analyzing ADCT Stock Performance
During the last five days, there has been a drop of approximately -7.45%. Over the course of the year, Adc Therapeutics SA shares have jumped approximately 79.52%. Shares of the company reached a 52-week high of $6.04 on 02/20/24 and a 52-week low of $1.45 on 01/04/24. A 50-day SMA is recorded $3.01, while a 200-day SMA reached $3.60. Nevertheless, trading volume fell to 0.53 million shares from 0.11 million shares the previous day.
Support And Resistance Levels for Adc Therapeutics SA (ADCT)
According to the 24-hour chart, there is a support level at 2.86, which, if violated, would cause prices to drop to 2.74. In the upper region, resistance lies at 3.16. The next price resistance is at 3.34. RSI (Relative Strength Index) is 46.71 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.01, which suggests the price will decrease in the coming days. Percent R is at 62.67%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
